参考文献 References
[1] Dorton A. The pituitary gland: Embryology, physiology, and pathophysiology.Neonatal Network,2000;19
(2)
: 9-17.
[2] Caffarini M, Orciani M, Trementino L, et al. Pituitary adenomas, stem cells, and cancer stem cells: What’s new?.J Endocrinol Investigation,2017;
: 1-9.
[3] Nishioka H, Inoshita N, Mete O, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas.Endocrine Pathol,2015;26
(4)
: 349-355.
[4] Greenman Y. Management of endocrine disease: Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas.Eur J Endocrinol,2017;177
(3)
: R113-R124.
[5] Greenman Y, Stern N. Optimal management of non-functioning pituitary adenomas.Endocrine,2015;50
(1)
: 51-55.
[6] Greenman Y, Ouaknine G, Veshchev I, et al. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: Markers of tumour quiescence and regrowth.Clin Endocrinol,2003;58
(6)
: 763-769.
[7] Chen Y, De Wang C, Su ZP, et al. Natural history of postoperative nonfunctioning pituitary adenomas: A systematic review and meta-analysis.Neuroendocrinol,2012;96
(4)
: 333-342.
[8] Reddy R, Cudlip S, Byrne JV, et al. Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma?.Eur J Endocrinol,2011;165
(5)
: 739-744.
[9] O’Sullivan EP, Woods C, Glynn N, et al. The natural history of surgically treated but radiotherapy‐naïve nonfunctioning pituitary adenomas.Clin Endocrinol,2009;71
(5)
: 709-714.
[10] McLaughlin N, Eisenberg AA, Cohan P, et al. Value of endoscopy for maximizing tumor removal in endonasal transsphenoidal pituitary adenoma surgery.J Neurosurg,2013;118
(3)
: 613-620.
[11] Messerer M, De Battista JC, Raverot G, et al. Evidence of improved surgical outcome following endoscopy for nonfunctioning pituitary adenoma removal: Personal experience and review of the literature.Neurosurg Focus,2011;30
(4)
: E11.
[12] Buchfelder M, Schlaffer S. Intraoperative magnetic resonance imaging for pituitary adenomas.Front Horm Res,2016;45
: 211.
[13] Berkmann S, Schlaffer S, Nimsky C, et al. Follow-up and long-term outcome of nonfunctioning pituitary adenoma operated by transsphenoidal surgery with intraoperative high-field magnetic resonance imaging.Acta Neurochirurgica,2014;156
(12)
: 2233-2243.
[14] Kuo JS, Barkhoudarian G, Farrell CJ, et al. Congress of neurological surgeons systematic review and evidence-based guideline on surgical techniques and technologies for the management of patients with nonfunctioning pituitary adenomas.Neurosurg,2016;79
(4)
: E536-538.
[15] Zhan X, Wang X, Long Y, et al. Heterogeneity analysis of the proteomes in clinically nonfunctional pituitary adenomas.BMC Medical Genomics,2014;7
(1)
: 69.
[16] Nishioka H, Inoshita N. New who classification of pituitary adenomas: Assessment of pituitary transcription factors and the prognostic histological factors.Brain Tumor Pathol,2018;
: 1-5.
[17] Saeger W, Lüdecke DK, Buchfelder M, et al. Pathohistological classification of pituitary tumors: 10 years of experience with the german pituitary tumor registry.Eur J Endocrinol,2007;156
(2)
: 203-213.
[18] Asa SL. Practical pituitary pathology: What does the pathologist need to know?.Arch Pathol Lab Med,2008;132
(8)
: 1231-1240.
[19] Mete O, Asa SL. Clinicopathological correlations in pituitary adenomas.Brain Pathol,2012;22
(4)
: 151-156.
[20] Nishioka H, Inoshita N, Sano T, et al. Correlation between histological subtypes and mri findings in clinically nonfunctioning pituitary adenomas.Endocrine Pathol,2012;23
(3)
: 151-156.
[21] Erickson D, Scheithauer B, Atkinson J, et al. Silent subtype 3 pituitary adenoma: A clinicopathologic analysis of the mayo clinic experience.Clin Endocrinol,2009;71
(1)
: 92-99.
[22] Balogun JA, Monsalves E, Juraschka K, et al. Null cell adenomas of the pituitary gland: An institutional review of their clinical imaging and behavioral characteristics.Endocrine Pathol,2015;26
(1)
: 63-70.
[23] Bradley K, Wass J, Turner H. Non‐functioning pituitary adenomas with positive immunoreactivity for acth behave more aggressively than acth immunonegative tumours but do not recur more frequently.Clin Endocrinol,2003;58
(1)
: 59-64.
[24] Mete O, Gomez-Hernandez K, Kucharczyk W, et al. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal pit-1 lineage adenomas.Modern Pathol,2016;29
(2)
: 131.
[25] Brochier S, Galland F, Kujas M, et al. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: A study of 142 patients.Eur J Endocrinol,2010;163
(2)
: 193-200.
[26] Tateno T, Kato M, Tani Y, et al. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (acth)-secreting pituitary tumors and silent corticotroph adenomas.Endocrine J,2009;56
(4)
: 579-584.
[27] Petrossians P, Ronci N, Socin HV, et al. Acth silent adenoma shrinking under cabergoline.Eur J Endocrinol,2001;144
(1)
: 51-57.
[28] Kanner AA, Corn BW, Greenman Y. Radiotherapy of nonfunctioning and gonadotroph adenomas.Pituitary,2009;12
(1)
: 15-22.
[29] Darzy KH, Shalet SM. Hypopituitarism as a consequence of brain tumours and radiotherapy.Pituitary,2005;8
(3-4)
: 203-211.
[30] Minniti G, Traish D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: Update after an additional 10 years.J Clin Endocrinol Metab,2005;90
(2)
: 800-804.
[31] Erfurth EM, Bülow B, Svahn-Tapper G, et al. Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors.J Clin Endocrinol Metab,2002;87
(11)
: 4892-4899.
[32] Minniti G, Jaffrain-Rea M-L, Osti M, et al. Radiotherapy for nonfunctioning pituitary adenomas: From conventional to modern stereotactic radiation techniques.Neurosurg Rev,2007;30
(3)
: 167-176.
[33] Sheehan JP, Starke RM, Mathieu D, et al. Gamma knife radiosurgery for the management of nonfunctioning pituitary adenomas: A multicenter study.J Neurosurg,2013;119
(2)
: 446-456.
[34] Minniti G, Scaringi C, Poggi M, et al. Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: Long-term clinical outcomes and volumetric mri assessment of tumor response.Eur J Endocrinol,2015;172
(4)
: 433-441.
[35] Honegger J, Prettin C, Feuerhake F, et al. Expression of ki-67 antigen in nonfunctioning pituitary adenomas: Correlation with growth velocity and invasiveness.J Neurosurg,2003;99
(4)
: 674-679.
[36] Olsson DS, Nilsson AG, Bryngelsson I-L, et al. Excess mortality in women and young adults with nonfunctioning pituitary adenoma: A swedish nationwide study.J Clin Endocrinol Metab,2015;100
(7)
: 2651-2658.
[37] Florio T, Barbieri F, Spaziante R, et al. Efficacy of a dopamine–somatostatin chimeric molecule, bim-23a760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: A multi-center study.Endocrine-Related Cancer,2008;15
(2)
: 583-596.
[38] Greenman Y, Tordjman K, Osher E, et al. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth.Clin Endocrinol,2005;63
(1)
: 39-44.
[39] Greenman Y, Cooper O, Yaish I, et al. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.Eur J Endocrinol,2016;175
(1)
: 63-72.
[40] Colao A, Di Somma C, Pivonello R, et al. Medical therapy for clinically non-functioning pituitary adenomas.Endocrine-Related Cancer,2008;15
(4)
: 905-915.
[41] Greenman Y, Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: Evidence for preferential sstr5 expression in the mammosomatotroph lineage.J Clin Endocrinol Metab,1994;79
(3)
: 724-729.
[42] Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (sstr1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.Eur J Endocrinol,2007;156
(1)
: 65-74.
[43] Zatelli MC, Piccin D, Bottoni A, et al. Evidence for differential effects of selective somatostatin receptor subtype agonists on α-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.J Clin Endocrinol Metab,2004;89
(10)
: 5181-5188.
[44] Florio T, Thellung S, Arena S, et al. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro.Eur J Endocrinol,1999;141
(4)
: 396-408.
[45] Luque RM, Ibáñez-Costa A, Neto LV, et al. Truncated somatostatin receptor variant sst5tmd4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.Cancer Lett,2015;359
(2)
: 299-306.
[46] Zatelli MC, Piccin D, Vignali C, et al. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.Endocrine-Related Cancer,2007;14
(1)
: 91-102.
[47] Lee M, Lupp A, Mendoza N, et al. Sstr3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary.Endocrine-Related Cancer,2015;22
(1)
: 111-119.
[48] Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3.Mol Endocrinol,1996;10
(12)
: 1688-1696.
[49] Theodoropoulou M, Stalla GK. Somatostatin receptors: From signaling to clinical practice.Front Neuroendocrinol,2013;34
(3)
: 228-252.
[50] Fleseriu M. Medical treatment of cushing disease: New targets, new hope.Endocrinol Metab Clin,2015;44
(1)
: 51-70.
[51] chmid HA, Brue T, Colao A, et al. Effect of pasireotide on glucose-and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.Endocrine,2016;53
(1)
: 210-219.
[52] Raverot G, Sturm N, De Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: A french multicenter experience.J Clin Endocrinol Metab,2010;95
(10)
: 4592-4599.
[53] Hirohata T, Asano K, Ogawa Y, et al. DNA mismatch repair protein (msh6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: The national cooperative study by the japan society for hypothalamic and pituitary tumors.J Clin Endocrinol Metab,2013;98
(3)
: 1130-1136.
[54] Zhao Y, Xiao Z, Chen W, et al. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating o6-methylguanine-DNA methyltransferase expression.Mol Med Rep,2015;12
(2)
: 2313-2322.
[55] Dai C, Zhang B, Liu X, et al. Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin b‐dependent and caspase‐dependent apoptotic pathways.Int J Cancer,2013;133
(8)
: 1982-1993.
[56] Kun Z, Yuling Y, Dongchun W, et al. Hif-1α inhibition sensitized pituitary adenoma cells to temozolomide by regulating presenilin 1 expression and autophagy.Tech Cancer Res Treat,2016;15
(6)
: NP95-NP104.
[57] Bergsma H, van Vliet EI, Teunissen JJ, et al. Peptide receptor radionuclide therapy (prrt) for gep-nets.Best Pract Res Clin Gastroenterol,2012;26
(6)
: 867-881.
[58] Maclean J, Aldridge M, Bomanji J, et al. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: Variable clinical response in preliminary evaluation.Pituitary,2014;17
(6)
: 530-538.
[59] Komor J, Reubi JC, Christ ER. Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma.Pituitary,2014;17
(3)
: 227-231.
[60] Sun L-C, H Coy D. Somatostatin receptor-targeted anti-cancer therapy.Curr Drug Delivery,2011;8
(1)
: 2-10.
[61] Lelle M, Kaloyanova S, Freidel C, et al. Octreotide-mediated tumor-targeted drug delivery via a cleavable doxorubicin–peptide conjugate.Mol Pharmaceutics,2015;12
(12)
: 4290-4300.
[62] Ledermann J, Canevari S, Thigpen T. Targeting the folate receptor: Diagnostic and therapeutic approaches to personalize cancer treatments.Ann Oncol,2015;26
(10)
: 2034-2043.
[63] Evans C-O, Reddy P, Brat DJ, et al. Differential expression of folate receptor in pituitary adenomas.Cancer Res,2003;63
(14)
: 4218-4224.
[64] Liu X, Ma S, Yao Y, et al. Differential expression of folate receptor alpha in pituitary adenomas and its relationship to tumor behavior.Neurosurg,2011;70
(5)
: 1274-1280.
[65] Liu X, Ma S, Dai C, et al. Antiproliferative, antiinvasive, and proapoptotic activity of folate receptor α-targeted liposomal doxorubicin in nonfunctional pituitary adenoma cells.Endocrinol,2013;154
(4)
: 1414-1423.
[66] Dworakowska D, Wlodek E, Leontiou C, et al. Activation of raf/mek/erk and pi3k/akt/mtor pathways in pituitary adenomas and their effects on downstream effectors.Endocrine-Related Cancer,2009;16
(4)
: 1329-1338.
[67] Noh T-W, Jeong HJ, Lee M-K, et al. Predicting recurrence of nonfunctioning pituitary adenomas.J Clin Endocrinol Metab,2009;94
(11)
: 4406-4413.
[68] Jia W, Sanders AJ, Jia G, et al. Expression of the mtor pathway regulators in human pituitary adenomas indicates the clinical course.Anticancer Res,2013;33
(8)
: 3123-3131.
[69] Rubinfeld H, Shimon I. Pi3k/akt/mtor and raf/mek/erk signaling pathways perturbations in non-functioning pituitary adenomas.Endocrine,2012;42
(2)
: 285-291.
[70] Zatelli MC, Minoia M, Filieri C, et al. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.J Clin Endocrinol Metab,2010;95
(2)
: 968-976.
[71] Lee M, Wiedemann T, Gross C, et al. Targeting pi3k/mtor signaling displays potent antitumor efficacy against nonfunctioning pituitary adenomas.Clin Cancer Res,2015;21
(14)
: 3204-3215.
[72] Cerovac V, Monteserin-Garcia J, Rubinfeld H, et al. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells.Cancer Res,2010;70
(2)
: 666-674.
[73] Jouanneau E, Wierinckx A, Ducray F, et al. New targeted therapies in pituitary carcinoma resistant to temozolomide.Pituitary,2012;15
(1)
: 37-43.